18-fluorodeoxyglucose PET in people with active myelopathy

18-fluorodeoxyglucose PET in people with active myelopathy

Eoin P. Flanagan, M.B., B.Ch., an assistant professor of neurology and an Autoimmune Neurology fellow at Mayo Clinic in Rochester, Minnesota, discusses his article appearing in the November 2013 issue of Mayo Clinic Proceedings, which suggests that PET scans may give a clue to the underlying etiology in patients with spinal cord disease.


Created by

Mayo Clinic